The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan
Issued December 7, 2022 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 2933.59.5300
Headings: 2933
Product description
Ruxolitinib Phosphate is the phosphate salt form of Ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor. It is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
CBP rationale
The applicable subheading for the Ruxolitinib Phosphate in bulk powder form will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.
Full text
N329297 December 7, 2022 CLA-2-29:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 2933.59.5300 Ms. Sheila Heerdt Ren Pharm International Ltd. 350 Jericho Turnpike, Suite 204 Jericho, NY 11753 RE: The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan Dear Ms. Heerdt: In your letter dated November 10, 2022, you requested a tariff classification ruling. Ruxolitinib Phosphate is the phosphate salt form of Ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor. It is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The applicable subheading for the Ruxolitinib Phosphate in bulk powder form will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” The rate of duty will be 6.5 percent ad valorem. Currently, Ruxolitinib Phosphate is not listed in the Pharmaceutical Appendix to the Tariff Schedule. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Ensifentrine (CAS No. 1884461-72-6) in bulk powder form, from Portugal
The tariff classification of Trilaciclib Dihydrochloride (CAS No. 1977495-97-8) and Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk form, from Taiwan
The tariff classification of Vibegron (CAS No. 1190389-15-1) in bulk form, from India
The tariff classification of Vericiguat (CAS No. 1350653-20-1) in bulk form and Verquvo® Tablets in dosage form, from Germany
The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9) in bulk form, from Spain
The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India
The tariff classification of Imatinib (CAS No. 152459-95-5) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk powder form, from Italy
The tariff classification of VITRAKVI™ capsules in dosage form and Larotrectinib (CAS No. 1223403-58-4) in bulk form, from the United States and imported from the United Kingdom
The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9), Spironolactone (CAS No. 52-01-7) and Ticagrelor (CAS No. 274693-27-5) in bulk form, from India
The tariff classification of Elagolix Sodium (CAS No. 832720-36-2) in bulk powder form, from Spain
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →